Bukwang Pharmaceutical Statistics

Total Valuation

Bukwang Pharmaceutical has a market cap or net worth of KRW 304.62 billion. The enterprise value is 270.82 billion.

Market Cap	304.62B
Enterprise Value	270.82B

Important Dates

The last earnings date was Monday, November 11, 2024.

Earnings Date	Nov 11, 2024
Ex-Dividend Date	n/a

Share Statistics

Bukwang Pharmaceutical has 68.45 million shares outstanding. The number of shares has increased by 0.72% in one year.

Current Share Class	n/a
Shares Outstanding	68.45M
Shares Change (YoY)	+0.72%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	19.14%
Owned by Institutions (%)	3.00%
Float	47.58M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.62
PB Ratio	1.36
P/TBV Ratio	n/a
P/FCF Ratio	15.04
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-8.58
EV / Sales	2.32
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	13.37

Financial Position

The company has a current ratio of 6.50, with a Debt / Equity ratio of 0.35.

Current Ratio	6.50
Quick Ratio	4.51
Debt / Equity	0.35
Debt / EBITDA	n/a
Debt / FCF	3.93
Interest Coverage	-9.31

Financial Efficiency

Return on equity (ROE) is -13.68% and return on invested capital (ROIC) is -7.67%.

Return on Equity (ROE)	-13.68%
Return on Assets (ROA)	-6.02%
Return on Capital (ROIC)	-7.67%
Revenue Per Employee	210.44M
Profits Per Employee	-56.95M
Employee Count	554
Asset Turnover	0.32
Inventory Turnover	1.47

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -26.92% in the last 52 weeks. The beta is -0.17, so Bukwang Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	-0.17
52-Week Price Change	-26.92%
50-Day Moving Average	4,922.20
200-Day Moving Average	5,722.83
Relative Strength Index (RSI)	32.02
Average Volume (20 Days)	141,615

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bukwang Pharmaceutical had revenue of KRW 116.58 billion and -31.55 billion in losses. Loss per share was -459.80.

Revenue	116.58B
Gross Profit	45.26B
Operating Income	-35.43B
Pretax Income	-36.37B
Net Income	-31.55B
EBITDA	-31.32B
EBIT	-35.43B
Loss Per Share	-459.80

Full Income Statement

Balance Sheet

The company has 109.21 billion in cash and 79.67 billion in debt, giving a net cash position of 29.54 billion or 431.48 per share.

Cash & Cash Equivalents	109.21B
Total Debt	79.67B
Net Cash	29.54B
Net Cash Per Share	431.48
Equity (Book Value)	229.26B
Book Value Per Share	3,282.55
Working Capital	161.66B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 21.74 billion and capital expenditures -1.49 billion, giving a free cash flow of 20.25 billion.

Operating Cash Flow	21.74B
Capital Expenditures	-1.49B
Free Cash Flow	20.25B
FCF Per Share	295.81

Full Cash Flow Statement

Margins

Gross margin is 38.82%, with operating and profit margins of -30.39% and -27.06%.

Gross Margin	38.82%
Operating Margin	-30.39%
Pretax Margin	-31.20%
Profit Margin	-27.06%
EBITDA Margin	-26.86%
EBIT Margin	-30.39%
FCF Margin	17.37%

Dividends & Yields

Bukwang Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.72%
Shareholder Yield	-0.72%
Earnings Yield	-10.33%
FCF Yield	6.65%

Dividend Details

Stock Splits

The last stock split was on December 29, 2020. It was a forward split with a ratio of 1.1.

Last Split Date	Dec 29, 2020
Split Type	Forward
Split Ratio	1.1

Scores

Bukwang Pharmaceutical has an Altman Z-Score of 3.42.

Altman Z-Score	3.42
Piotroski F-Score	n/a